398 related articles for article (PubMed ID: 22506582)
1. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
[TBL] [Abstract][Full Text] [Related]
2. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.
Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
Aliment Pharmacol Ther; 2013 Jan; 37(2):214-24. PubMed ID: 23190161
[TBL] [Abstract][Full Text] [Related]
3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
4. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
[TBL] [Abstract][Full Text] [Related]
6. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
[TBL] [Abstract][Full Text] [Related]
7. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy.
Gu J; Remzi FH; Shen B; Vogel JD; Kiran RP
Dis Colon Rectum; 2013 Nov; 56(11):1243-52. PubMed ID: 24104999
[TBL] [Abstract][Full Text] [Related]
8. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
Teisner AS; Ainsworth MA; Brynskov J
Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
Syed A; Cross RK; Flasar MH
Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
[TBL] [Abstract][Full Text] [Related]
12. Postoperative complications and mortality following colectomy for ulcerative colitis.
de Silva S; Ma C; Proulx MC; Crespin M; Kaplan BS; Hubbard J; Prusinkiewicz M; Fong A; Panaccione R; Ghosh S; Beck PL; Maclean A; Buie D; Kaplan GG
Clin Gastroenterol Hepatol; 2011 Nov; 9(11):972-80. PubMed ID: 21806954
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
[TBL] [Abstract][Full Text] [Related]
14. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
15. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.
Vester-Andersen MK; Prosberg MV; Jess T; Andersson M; Bengtsson BG; Blixt T; Munkholm P; Bendtsen F; Vind I
Am J Gastroenterol; 2014 May; 109(5):705-14. PubMed ID: 24642581
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study.
Ward ST; Mytton J; Henderson L; Amin V; Tanner JR; Evison F; Radley S
Colorectal Dis; 2018 May; 20(5):416-423. PubMed ID: 29059479
[TBL] [Abstract][Full Text] [Related]
17. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
18. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis.
Murthy SK; Steinhart AH; Tinmouth J; Austin PC; Daneman N; Nguyen GC
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1032-9. PubMed ID: 23061526
[TBL] [Abstract][Full Text] [Related]
19. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
20. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study.
Kaplan GG; Seow CH; Ghosh S; Molodecky N; Rezaie A; Moran GW; Proulx MC; Hubbard J; MacLean A; Buie D; Panaccione R
Am J Gastroenterol; 2012 Dec; 107(12):1879-87. PubMed ID: 23165448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
